# US 2016/0238598 A1 · Method for stabilizing glycerophospholipids and reagents using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0238598 A1
- Document ID: US20160238598A1
- Status: Published application
- Kind: A1
- Application number: 15/137,345
- Filed: 2016-04-25
- Published: 2016-08-18
- Earliest claimed: 2010-03-31
- Assignees: Sekisui Medical Co., Ltd.
- Applicants: Sekisui Medical Co., Ltd.
- Inventors: Takayuki ABE; Tetsuya OTA
- Web page: https://patentgrep.com/patent/US20160238598A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/54393: {Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding}
- G01N 33/571: for venereal disease, e.g. syphilis, gonorrhoea {(herpes G01N33/56994; chlamydia G01N33/56927)}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2405/04: Phospholipids, i.e. phosphoglycerides
- G01N 2405/06: Glycophospholipids, e.g. phosphatidyl inositol
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed is an accurate and stable immunoassay reagent using a glycerophospholipid and a method for stabilizing the reagent. The reagent for assaying an analyte in blood by immune reaction with an antigen when the analyte is an antibody or with an antibody when the analyte is an antigen, wherein a glycerophospholipid and a polyvinylpyrrolidone are incorporated into the immune reaction system.

## Claims

### Claim 1

A reagent for assaying for an antibody or antigen by an immune reaction, comprising:
a glycerophospholipid in the form of a solution or a dispersion; and
a polyvinylpyrrolidone.

### Claim 2 (depends on 1)

The reagent of claim 1, wherein the glycerophospholipid is at least one selected from the group consisting of phosphatidic acid, phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine, and phosphatidylserine.

### Claim 3 (depends on 1)

The reagent of claim 1, further comprising:
a phospholipid antigen.

### Claim 4 (depends on 3)

The reagent of claim 3, wherein the phospholipid antigen is supported on an insoluble carrier.

### Claim 5 (depends on 3)

The reagent of claim 3, wherein the phospholipid antigen is an antigen for an antibody generated in blood through infection with syphilis.

### Claim 6 (depends on 3)

The reagent of claim 3, wherein the phospholipid antigen is an antigen for an antibody generated in blood through anti-phospholipid antibody syndrome, which is an autoimmune disease.

### Claim 7

A method for assaying a sample for an antibody or an antigen by an immune reaction, comprising:
contacting the sample with an antibody when assaying for an antigen, or with an antigen when assaying for an antibody, such that an immune reaction occurs between the antigen and the antibody,
wherein the contacting occurs in the presence of a glycerophospholipid in the form of solution or dispersion and a polyvinylpyrrolidone.

### Claim 8 (depends on 7)

The method of claim 7, wherein the glycerophospholipid is at least one selected from the group consisting of phosphatidic acid, phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine, and phosphatidylserine.

### Claim 9 (depends on 7)

The method according to claim 7,
wherein the sample contains an anti-phospholipid antibody, and
the antibody is a phospholipid antigen.

### Claim 10 (depends on 9)

The method of claim 9, wherein the phospholipid antigen is supported on an insoluble carrier.

### Claim 11 (depends on 9)

The method of claim 9, wherein the anti-phospholipid antibody is an anti-syphilis phospholipid antibody generated in blood through infection with syphilis.

### Claim 12 (depends on 9)

The method of claim 9, wherein the anti-phospholipid antibody is an anti-phospholipid antibody generated in blood through anti-phospholipid antibody syndrome.

### Claim 13

A method for stabilizing a liquid comprising a glycerophospholipid in the form of solution or dispersion, the method comprising:
including polyvinylpyrrolidone into the liquid comprising glycerophospholipid in the form of solution or dispersion.

### Claim 14

(canceled)

### Claim 15 (depends on 2)

The reagent of claim 2, further comprising:
a phospholipid antigen.

### Claim 16 (depends on 15)

The reagent of claim 15, wherein the phospholipid antigen is supported on an insoluble carrier.

### Claim 17 (depends on 15)

The reagent of claim 15, wherein the phospholipid antigen is an antigen for an antibody generated in blood through infection with syphilis.

### Claim 18 (depends on 15)

The reagent of claim 15, wherein the phospholipid antigen is an antigen for an antibody generated in blood through anti-phospholipid antibody syndrome.

### Claim 19 (depends on 8)

The method according to claim 8,
wherein the sample contains an anti-phospholipid antibody, and
the antibody is a phospholipid antigen.

### Claim 20 (depends on 19)

The method of claim 19, wherein the phospholipid antigen is supported on an insoluble carrier.

### Claim 21 (depends on 19)

The method of claim 19, wherein the anti-phospholipid antibody is an anti-syphilis phospholipid antibody generated in blood through infection with syphilis or an anti-phospholipid antibody generated in blood through anti-phospholipid antibody syndrome.
